Profile | GDS2987 / GI_16357469-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 5 | 19 |
GSM215244 | HMVEC_vehicle_rep2 | 10 | 26 |
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | 19.3 | 45 |
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 15.8 | 30 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 26.3 | 47 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | 0.6 | 1 |
GSM215297 | PASMC_vehicle_rep1 | 6.2 | 10 |
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | ||
GSM215313 | PASMC_atorvastatin_rep3 | ||
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | ||
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 16.8 | 32 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 34.1 | 50 |
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 11.2 | 21 |
GSM215329 | PASMC_SLx2119_rep3 | ||
GSM215330 | Fibroblasts_vehicle_rep1 | 20.7 | 43 |
GSM215331 | Fibroblasts_vehicle_rep2 | 35.9 | 63 |
GSM215332 | Fibroblasts_vehicle_rep3 | 32 | 63 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 25.7 | 54 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 29.3 | 59 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 26.5 | 53 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 51.3 | 70 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 60.4 | 71 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 39 | 65 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 36.1 | 65 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 32.4 | 62 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 16.5 | 39 |